Drugs / actilysis
actilysis
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01670474 | Jan 2011 → Nov 2012 | thrombotic disease | Centre Hospitalier du Centre du Valais | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | actilysis | “Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min.” NCT01670474 ↗ |
| Known as | Alteplase | “At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim,...” NCT01670474 ↗ |
| Known as | rt-PA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01670474 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant tissue plasminogen activator (rt-PA)” NCT01670474 ↗ |